{
  "docId": "019de073-d2da-762c-9a26-b97a59cfec30",
  "docSlug": "f7af69768ee002be4e2317aa5e807561",
  "documentTitle": "Revelation Biosciences | Investor Presentation Deck | 18 slides",
  "authorId": "revelation-biosciences",
  "authorName": "Revelation Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 18,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The diagram shows the signaling pathway from extracellular receptor binding to nuclear cytokine induction.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-d2da-762c-9a26-b97a59cfec30/4",
  "deckHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30",
  "deckJsonHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30.json",
  "deckAnchorHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "image",
      "text": "Mechanism of action diagram showing TLR4 pathway",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35cf755e-2cf8-4549-afce-cc70922b1575",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "list",
      "text": "Prevention and treatment of hospital acquired infection via trained immunity (REVTx-100)\nRecruit immune cells to the mucosa to augment the local and systemic adaptive immune response (REVTx-200)\nTreatment of chronic inflammatory disease such as CKD and NASH (REVTx-300)\nTreatment of food allergies and allergic rhinitis (REVTx-99b)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec61483b-06ee-41a3-a75d-5b42b56e4de8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.03,
        "y": 0.0085
      },
      "kind": "paragraph",
      "text": "Revelation has developed propriety formulations and methods of use to deliver phosphorylated hexaacyl disaccharide (PHAD) to the local intranasal cavity or systemically to treat various diseases",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57e5addb-a28b-42b6-8a5a-20750ec9ad2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1c1d696-ddc4-44f1-8125-f91d3121c1f9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 4,
      "beatId": "2182d072-e6b9-49a0-b466-5a839998139b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-15 describe various solutions, including PHAD, REVTx-100, REVTx-200, and REVDx-501.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f450b0af-f83a-4370-8b16-ab5011fb13d6",
      "evidence": "Slides 4-15 describe PHAD and its applications.",
      "position": 1,
      "objective": "Why is PHAD a well-defined TLR4 agonist with multiple potential applications?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}